Morgan Stanley Atossa Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 160,912 shares of ATOS stock, worth $123,902. This represents 0.0% of its overall portfolio holdings.

Number of Shares

160,912

Previous 284,187 43.38%

Holding current value

$123,902

Previous $190,000 30.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$0.59 - $1.03 $72,732 - $126,973	-123,275 Reduced 43.38%	160,912 $133,000
Q1 2025 May 15, 2025	SELL	$0.67 - $1.01 $112,566 - $169,689	-168,009 Reduced 37.15%	284,187 $190,000
Q4 2024 Feb 14, 2025	SELL	$0.94 - $1.62 $5,004 - $8,624	-5,324 Reduced 1.16%	452,196 $425,000
Q3 2024 May 14, 2025	BUY	$1.09 - $1.52 $1,490 - $2,077	1,367 Added 0.3%	457,520 $695,000
Q3 2024 Nov 14, 2024	BUY	$1.09 - $1.52 $1,490 - $2,077	1,367 Added 0.3%	457,520 $695,000
Q2 2024 May 14, 2025	BUY	$1.03 - $2.1 $4,075 - $8,309	3,957 Added 0.88%	456,153 $542,000
Q2 2024 Oct 17, 2024	SELL	$1.03 - $2.1 $318,537 - $649,446	-309,260 Reduced 40.4%	456,153 $542,000
Q2 2024 Aug 14, 2024	SELL	$1.03 - $2.1 $318,537 - $649,446	-309,260 Reduced 40.4%	456,153 $542,000
Q1 2024 Oct 17, 2024	BUY	$0.8 - $1.89 $247,408 - $584,501	309,260 Added 67.8%	765,413 $1.38 Million
Q1 2024 Aug 16, 2024	BUY	$0.8 - $1.89 $520,485 - $1.23 Million	650,607 Added 566.7%	765,413 $1.38 Million
Q1 2024 May 15, 2024	BUY	$0.8 - $1.89 $520,485 - $1.23 Million	650,607 Added 566.7%	765,413 $1.38 Million
Q4 2023 Aug 16, 2024	SELL	$0.63 - $0.98 $215,048 - $334,520	-341,347 Reduced 74.83%	114,806 $101,000
Q4 2023 Feb 13, 2024	SELL	$0.63 - $0.98 $22,019 - $34,251	-34,951 Reduced 23.34%	114,806 $101,000
Q3 2023 Nov 15, 2023	SELL	$0.74 - $1.35 $34,139 - $62,280	-46,134 Reduced 23.55%	149,757 $110,000
Q2 2023 Aug 14, 2023	BUY	$0.6 - $1.28 $15,081 - $32,174	25,136 Added 14.72%	195,891 $246,000
Q1 2023 May 15, 2023	SELL	$0.59 - $0.91 $13,531 - $20,870	-22,935 Reduced 11.84%	170,755 $122,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.01 $4,942 - $9,983	9,885 Added 5.38%	193,690 $102,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $67,719 - $94,146	-82,585 Reduced 31.0%	183,805 $152,000
Q2 2022 Oct 27, 2022	BUY	$0.85 - $1.28 $100,975 - $152,057	118,795 Added 80.49%	266,390 $291,000
Q2 2022 Aug 15, 2022	BUY	$0.85 - $1.28 $100,975 - $152,057	118,795 Added 80.49%	266,390 $291,000
Q1 2022 Oct 27, 2022	SELL	$1.11 - $1.74 $131,862 - $206,703	-118,795 Reduced 44.59%	147,595 $184,000
Q1 2022 May 13, 2022	SELL	$1.11 - $1.74 $7,067 - $11,078	-6,367 Reduced 4.14%	147,595 $184,000
Q4 2021 Feb 14, 2022	SELL	$1.6 - $3.27 $134,662 - $275,216	-84,164 Reduced 35.34%	153,962 $246,000
Q3 2021 Nov 15, 2021	BUY	$2.89 - $6.4 $688,184 - $1.52 Million	238,126 New	238,126 $776,000

Others Institutions Holding ATOS

# of Institutions

Shares Held

28.6M

Call Options Held

12.7K

Put Options Held

92.9K

View Full List

About ATOSSA THERAPEUTICS, INC.

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $97.5M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

More about ATOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account